Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies.

Ishii, H; Dumon, K R; Vecchione, A; Fong, L Y; Baffa, R; Huebner, K; Croce, C M

Ishii, H; Dumon, K R; Vecchione, A; Fong, L Y; Baffa, R; Huebner, K; Croce, C M.

Affiliation

Ishii H; Kimmel Cancer Center, Thomas Jefferson University, 233 S 10th St, Philadelphia, PA 19107-5799, USA.

JAMA ; 286(19): 2441-9, 2001 Nov 21.

Article in En | MEDLINE | ID: mdl-11712940

Subject(s)

Acid Anhydride Hydrolases; Genes, Tumor Suppressor; Genetic Therapy; Neoplasm Proteins/genetics; Neoplasms/therapy; Precancerous Conditions/therapy; Animals; Evaluation Studies as Topic; Humans; Immunohistochemistry; Mice; Models, Animal; Neoplasm Proteins/metabolism; Neoplasms/genetics; Neoplasms/metabolism; Neoplasms/pathology; Precancerous Conditions/genetics; Precancerous Conditions/metabolism; Precancerous Conditions/pathology; Transfection

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Precancerous Conditions / Genetic Therapy / Genes, Tumor Suppressor / Acid Anhydride Hydrolases / Neoplasm Proteins / Neoplasms Type of study: Diagnostic_studies / Evaluation_studies / Prognostic_studies / Systematic_reviews Limits: Animals / Humans Language: En Journal: JAMA Year: 2001 Document type: Article

Search on Google

XML

PubMed Links